Skip to main content
Trident Lifeline Limited logo

Trident Lifeline Limited — Investor Relations & Filings

Ticker · 543616 ISIN · INE0MKA01014 LEI · 335800GZM91Q21HGZI21 BSE.NS Manufacturing
Open in API
Filings indexed 7 across all filing types
Latest filing 2026-06-13 Board/Management Inform…
Country IN India
Listing BSE.NS 543616

About Trident Lifeline Limited

https://www.tridentlifeline.com

Trident Lifeline Limited is a pharmaceutical company engaged in the manufacturing, marketing, and distribution of a wide range of pharmaceutical formulations. The company's product portfolio encompasses various therapeutic areas, including anti-infectives, analgesics, anti-inflammatory drugs, cardiovascular agents, and gastrointestinal treatments. Their dosage forms include tablets, capsules, liquid orals, and topical preparations. Trident Lifeline operates with a focus on quality compliance, adhering to international standards such as WHO-GMP. The company serves both domestic and international markets through its export operations, providing affordable healthcare solutions. Their business model integrates research and development with efficient supply chain management to deliver diverse medicinal products to healthcare providers and patients globally.

Recent filings

Filing Released Lang Actions
The Board of Directors in their meeting held on today has approved appointmnt of Ms. Smita Davda and Mr. Sachin Bhandari as Additional Non Executive Independent Director for a period of ....
Board/Management Information Classification · 95% confidence The document is an announcement from the Board of Directors of Trident Lifeline Limited. It details the approval of appointments of Ms. Smita Kiran Davda and Mr. Sachin Bhandari as Additional Non-Executive Independent Directors, including their profiles and terms of appointment. It also mentions the approval of migration of securities to the main board of stock exchanges and other governance-related items in the board meeting held on June 13, 2026. This document is focused on board and management changes and disclosures required under SEBI Listing Regulations. It is not an annual report, financial results, or audit report. Hence, based on its content centered on director appointments and related disclosures, it falls under Board/Management Information (MANG).
2026-06-13 English
The Board of Directors of the Company in their meeting held today i.e. Saturday, June 13, 2026 have 1. approved Appointment of Ms. Smita Kiran Davda as an Additional Director of the Company ....
Board/Management Information Classification · 95% confidence The document is an official announcement addressed to the stock exchange about outcomes of a Board meeting held on June 13, 2026. It primarily communicates the approval of the appointment of two individuals as Additional Non-Executive Independent Directors, details of these appointments including biographies and terms, and other corporate governance matters such as securities migration and postal ballot approval. There is no full financial report, audit opinion, earnings data, or interim period financial analysis in the text. The document is focused on changes in the company's board structure and management. Given the detailed disclosures about director appointments and related regulatory references (SEBI regulations), the document fits the category of Board/Management Information (MANG). The document length (9243 characters) and detailed contents also do not suggest it is merely a report publication announcement or a regulatory filing. Therefore, the filing classification is MANG with high confidence.
2026-06-13 English
We wish to inform to the Exchange that TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421), a subsidiary company has made Private Placement of equity shares to other shareholders. ....
Capital/Financing Update Classification · 90% confidence The document is an Exchange disclosure under Regulation 30 of SEBI LODR dated 09.06.2026 announcing a private placement of equity shares by the subsidiary (Trident Mediquip Limited) and the consequent change in shareholding of the parent (Trident Lifeline Limited). It provides details of the equity issuance and resulting shareholding percentages. This is a capital‐raising/financing transaction disclosure rather than a full financial report or management change. Therefore it is classified as a Capital/Financing Update.
2026-06-09 English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shikha Bafna
Major Shareholding Notification Classification · 90% confidence The document is a disclosure under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, detailing the number and percentage of shares acquired by an acquirer (Shikha Ashish Bafna), before and after the acquisition, including mode and dates. This corresponds to a notification of changes in significant share ownership (crossing thresholds). Therefore it matches the “Major Shareholding Notification” category.
2026-06-05 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hardik Desai Family Trust
Major Shareholding Notification Classification · 90% confidence The document is a disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011—Regulation 29(2), providing details of acquisition of shares by a promoter group (Hardik Desai Family Trust). This is a notification of changes in significant share ownership levels. According to the classification definitions, this falls squarely under Major Shareholding Notification (Code: MRQ).
2026-06-01 English
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the half year and year ended ....
Investor Presentation Classification · 95% confidence The document is titled 'Earnings Presentation-H2 & FY26' and is addressed pursuant to SEBI regulations, indicating it is a formal disclosure related to financial results. It includes detailed company overview, product portfolio, global footprint, leadership, strategy, and financial highlights for the half year and full fiscal year ended March 31, 2026. The content is structured as a presentation with slides and detailed narrative, typical of investor presentations. It is not a brief announcement, certification, or voting result. The document length (15,000 characters) and detailed content confirm it is a presentation rather than a full annual or interim report. Therefore, the most appropriate classification is Investor Presentation (IP).
2026-05-09 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.